Lucera Erick 4

What Happened

• Lucera Erick, Dyne Therapeutics’ Chief Financial Officer, received equity awards on Feb 12, 2026: 65,000 restricted stock units (RSUs) and a 105,000‑share derivative award (an option). Both grants are reported at $0.00 (no cash paid by the insider at grant). These are compensation/retention awards, not open‑market purchases or sales.

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (filed five days after the transaction date; this appears later than the typical 2 business‑day Form 4 deadline).
• Consideration: $0.00 for both the 65,000 RSUs and the 105,000‑share derivative grant.
• Vesting: The 65,000 RSUs vest in equal quarterly installments over four years (first vesting installment on May 12, 2026). The option’s underlying shares vest in equal monthly installments over four years through February 12, 2030.
• Shares owned after transaction: The filing excerpt provided does not state a total post‑transaction beneficial ownership number; footnote F2 indicates the filing “includes 131,100 unvested RSUs.”
• Footnotes from the filing:
  • F1: The 65,000 award consists of RSUs; one RSU = one share upon vesting; quarterly vesting over four years beginning May 12, 2026.
  • F2: Filing “includes 131,100 unvested RSUs.”
  • F3: The derivative (option) was granted Feb 12, 2026; underlying shares vest monthly over four years through Feb 12, 2030.

Context

• RSUs convert to actual shares only as they vest; the option grant must vest and then be exercised before shares are received or sold. These grants are standard executive compensation/retention vehicles and do not involve an immediate cash purchase or sale by the insider, so they should not be read as a direct bullish or bearish trading signal.